Violation Tracker Individual Record
Company:Janssen Pharmaceuticals, Inc.
Date:August 30, 2012
Offense Group:healthcare-related offenses
Primary Offense:off-label or unapproved promotion of medical products
Janssen Pharmaceuticals, Inc. and its parent company Johnson & Johnson agreed to pay $181 million to resolve multistate litigation alleging improper marketing and advertising of the powerful anti-psychotic drugs Risperdal and Invega.
Level of Government:state
Action Type:agency action
Agency:Multistate Attorneys General Case
Civil or Criminal Case:civil
HQ Country of Parent:USA
HQ State of Parent:New Jersey
Ownership Structure of Parent:publicly traded
Major Industry of Parent:pharmaceuticals
Specific Industry of Parent:pharmaceuticals
Source Notes:If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.